Search

Displaying results 3001 - 3010 of 7186 in total
  1. Drug

    Diflorasone

    go.drugbank.com/drugs/DB00223
    Approved

    Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

  2. Drug

    Hydroxyproline

    go.drugbank.com/drugs/DB08847
    Approved

    Therapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds.

    Mixtures: Ouhi Cell Power No 1 Essence, Ouhi Cell Power No 1 EyeProducts: O Hui Wrinkle Science Wrinkle Repair, O Hui Wrinkle Science Deep Wrinkle Treatment
  3. Drug

    Nebivolol

    go.drugbank.com/drugs/DB04861
    ApprovedInvestigational

    [A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].

    Mixtures: LOBI HZProducts: CORETEL-N
  4. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors. … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.

  5. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and

  6. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. … [A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.

  7. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2.

  8. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.

  9. Drug

    Hexafluronium

    go.drugbank.com/drugs/DB00941
    Approved

    It is known to bind and block the activity of plasma cholinesterases. … Hexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.

  10. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. … [L64039,L64040] It is the first targeted cancer medicine approved from the class of RAS(ON) multi-selective and mutant-selective inhibitors.[L64041]